Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PYS phage
- Development stage
- Preclinical
- Lead developer
- International Center for Chemical and Biological Science
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
PYS phage (also referred to as P¥S phage) is a lytic bacteriophage belonging to the *Autoscriptoviridae* family [1]. It is being developed as a topical hydrogel formulation for the treatment of burn wound infections caused by carbapenem-resistant *Pseudomonas aeruginosa* (CRPA) [1]. Isolated from environmental samples, PYS phage exhibits high specificity and lytic activity against CRPA, significant thermal stability (4–60°C), pH stability (5–9), and a short latency period of 15 minutes [1]. In preclinical models, treatment with the phage-loaded hydrogel significantly reduces bacterial burden, enhances biofilm eradication, improves wound closure rates, and promotes re-epithelialization and tissue recovery [1].
- Other names
- P¥S phage
02
Targets
P. aeruginosa (Pseudomonas aeruginosa)
Beyond the preview
Go deeper on PYS phage.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PYS phage.